Recurrent hepatitis C: Worse outcomes established, interventions still inadequate

Liver Transplantation

Volumn 13, Issue 5, 2007, Pages 641-643

  Berenguer, Marina ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT; PEGINTERFERON; PREDNISONE; RIBAVIRIN; STEROID;

DEATH; DISEASE COURSE; DISEASE SEVERITY; DONOR SELECTION; DRUG WITHDRAWAL; EDITORIAL; GRAFT INFECTION; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNOCOMPETENCE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; MEDICAL RESEARCH; ORGAN DONOR; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT INFECTION; SURVIVAL RATE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

DISEASE PROGRESSION; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RECURRENCE; TIME FACTORS;

EID: 34249019838     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21136     Document Type: Editorial

References (19)

1. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006;355:2444-2451.
2. Samuel D, Forns X, Berenguer M, Trautwein C, Burroughs A, Rizzetto M, et al. Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). J Hepatol 2006;45: 127-143.
3. Berenguer M, Palau A, Fernández A, Benlloch S, Aguilera V, Prieto M, et al. Efficacy, predictors of response and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006;12:1067-1076.
4. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M. et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32:673-684.
5. Forman LM, Dewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation.. Gastroenterology 2002;122:889-896.
6. Berenguer M, Prieto M, San Juan F, Rayón M, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002;36:202-210.
7. Neumann UP, Berg T, Bahra M, Puhl G, Guckelberger O, Langrehr JM, et al. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation 2004;77:226-231.
8. Belli L, Burroughs AK, Burra P, Alberti AB, Samonakis D, Calogero C, et al. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients. Results of a long term retrospective study. Liver Transpl 2007;13:733-740.
9. Thuluvath P, Krok K, Segev D, Yoo D. Trends in post liver transplant survival in patients with hepatitis C between 1991 and 2001 in the USA. Liver Transpl 2007;13:719-724.
10. Charlton M, Ruppert K, Belle SH, Bass N, Schafer D, Wiesner RH, et al. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database. Liver Transpl 2004;10:1120-1130.
11. Russo MA, Galanko JA, Zacks SL, Beavers KL, Fried MW, Shrestha. R. Impact of donor age and year of transplant on graft survival in liver transplant recipients with chronic hepatitis C. Am J Transpl 2004;4:1133-1138.
12. Berenguer M. What determines the natural history of recurrent hepatitis C? J Hepatol 2005;42:448-479.
13. Nelson DR, Soldevila-Pico C, Reed A, Abdelmaleck MF, Hemming AW, Van der Werf WJ, et al. The effect of anti-interleukin-2 receptor therapy on the course of hepatitis C recurrence after liver transplantation. Liver Transpl 2001; 7:1064-1070.
14. Samonakis DN, Triantos CK, Thalheimer U, Quaglia A, Leandro G, Teixeira R, et al. Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl 2005;11:384-385.
15. Mutimer DJ, Gunson B, Chen J, Berenguer J, Neuhaus P, Castaing D, et al. Impact of donor age and year of transplantation on graft and patient survival following liver transplantation for hepatitis C virus. Transplantation 2006;81:7-14.
16. Futagawa Y, Terasaki PI, Waki K, Cai J, Gjertson DW. No improvement in long-term liver transplant graft survival in the last decade: an analysis of the UNOS data. Am J Transpl 2006;6:1398-1406.
17. Berenguer M, Aguilera V, Prieto M, San Juan F, Rayón JM, Benlloch S, et al. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol 2006;44:717-722.
18. Foxton MR, Quaglia A, Muiesan P, Henegan MA, Portmann B, Norris S, et al. The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. Am J Transplanl 2006;6:1922-1929.
19. Rimola A, Londoño MC, Guevara G, Bruguera M, Navasa M, Forns X, et al. Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation. Transplantation 2004;78:686-691.